Chiesi Farmaceutici S.p.A.

Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019

Retrieved on: 
Thursday, July 16, 2020
ebit, Earnings before interest and taxes, Chiesi Farmaceutici S.p.A.

CARY, N.C., July 16, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the publication of the Groups 2019 Report.

Key Points: 
  • CARY, N.C., July 16, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the publication of the Groups 2019 Report.
  • EBIT (Earnings Before Interest and Taxes) increased from 362.7 million in 2018 to 424.7 million in 2019 (21.3% in 2019 compared to 20.5% in 2018).
  • The number of people employed worldwide by Chiesi in 2019 reached around 6,000, of which more than 50% are women.
  • 2019 went beyond expectations and enabled the company to reach a turnover of almost 2 billion, confirms Ugo Di Francesco, CEO of the Chiesi Group.

Bioasis and Chiesi Group to Host Webcast on July 16, 2020

Retrieved on: 
Thursday, July 9, 2020
Oncology, Health, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Rare disease, Lysergic acid diethylamide, Drugs, Chemical substances, Chiesi Farmaceutici S.p.A., Lysosomal Storage Disorders, Chiesi Global Rare Diseases, Chiesi Group, Bioasis

Under the terms of the Research Collaboration and License Agreement (the Agreement), Chiesi Group will pay Bioasis an upfront payment of US$3 million.

Key Points: 
  • Under the terms of the Research Collaboration and License Agreement (the Agreement), Chiesi Group will pay Bioasis an upfront payment of US$3 million.
  • Chiesi Group will be responsible for all costs associated with research, development and commercialization of the four undisclosed LSD programs.
  • A replay of the webcast (using the same link provided) will be available for one month following the conclusion of the event.
  • Chiesi Global Rare Diseases is a business unit of the Chiesi Group, established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders.

Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance

Retrieved on: 
Monday, June 29, 2020
Oncology, Health, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Rare disease, Chiesi Farmaceutici S.p.A.

Chiesi Group will be responsible for all costs associated with research, development and commercialization of the four undisclosed LSD programs.

Key Points: 
  • Chiesi Group will be responsible for all costs associated with research, development and commercialization of the four undisclosed LSD programs.
  • With this collaboration, we are taking our commitment to bringing innovative therapies to rare disease patients, including those living with LSDs, to an entirely new level, said Giacomo Chiesi, Head of Chiesi Global Rare Diseases, a business unit of Chiesi Group.
  • Chiesi Global Rare Diseases and Bioasis will host a joint webcast with details to be announced.
  • Chiesi Global Rare Diseases is a business unit of the Chiesi Group, established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders.

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

Retrieved on: 
Thursday, May 28, 2020
Galactosides, Galactosidases, Food and Drug Administration, Health, Chiesi Farmaceutici S.p.A., Articles, Protalix BioTherapeutics

Pegunigalsidase alfa, or PRX-102, was granted Fast Track designation by the FDA in January 2018.

Key Points: 
  • Pegunigalsidase alfa, or PRX-102, was granted Fast Track designation by the FDA in January 2018.
  • Upon the BLA approval, if approved, the Company will be eligible to receive a milestone payment from Chiesi.
  • Pegunigalsidase alfa (PRX102) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant -Galactosidase-A enzyme.
  • Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders.

Chiesi USA increases support measures for employees, patients and community partners in response to COVID-19 pandemic

Retrieved on: 
Tuesday, March 31, 2020
Articles, Global health, Pandemic, Chiesi Farmaceutici S.p.A.

CARY, N.C., March 31, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced a range of new measures to support employees, patients and healthcare providers in response to the continuing COVID-19 pandemic.

Key Points: 
  • CARY, N.C., March 31, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced a range of new measures to support employees, patients and healthcare providers in response to the continuing COVID-19 pandemic.
  • The measures followed actions taken by Chiesi Group, which recently created a 3 million fund to support the response to coronavirus in Italy and sent additional resources to employees around the globe.
  • In response to the pandemic, Chiesi USA created the Chiesi Emergency Management Team to implement measures to safeguard the health and safety of all employees.
  • As a Certified B Corporation, Chiesi USA is committed to having a positive impact on society during this critical time.

Chiesi Global Rare Diseases Recognizes Rare Disease Day and Highlights Plans to Expand Focus on Patient Advocacy in 2020

Retrieved on: 
Thursday, February 27, 2020
Branches of biology, Medicine, Rare disease, Lysosomal storage disease, Disease, Inborn errors of metabolism, Lysosome, Chiesi Farmaceutici S.p.A.

Chiesi Global Rare Diseases was established in February 2020 to target new treatments for rare diseases, with a priority focus on developing therapies for lysosomal storage disorders and rare hematology and ophthalmology disorders.

Key Points: 
  • Chiesi Global Rare Diseases was established in February 2020 to target new treatments for rare diseases, with a priority focus on developing therapies for lysosomal storage disorders and rare hematology and ophthalmology disorders.
  • "Following the launch of our new rare disease business unit, we were honored to meet with many members of the lysosomal storage disease community at the recent WORLDSymposium meeting in Orlando," said Giacomo Chiesi, Head of Chiesi Global Rare Diseases.
  • In 2020, members of the leadership team at Chiesi Global Rare Diseases will meet with leaders from advocacy organizations as well as individual families affected by rare diseases during a global "listening tour."
  • Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders.

Chiesi Global Rare Diseases Recognizes Rare Disease Day and Highlights Plans to Expand Focus on Patient Advocacy in 2020

Retrieved on: 
Thursday, February 27, 2020
Branches of biology, Medicine, Rare disease, Lysosomal storage disease, Disease, Inborn errors of metabolism, Lysosome, Chiesi Farmaceutici S.p.A.

Chiesi Global Rare Diseases was established in February 2020 to target new treatments for rare diseases, with a priority focus on developing therapies for lysosomal storage disorders and rare hematology and ophthalmology disorders.

Key Points: 
  • Chiesi Global Rare Diseases was established in February 2020 to target new treatments for rare diseases, with a priority focus on developing therapies for lysosomal storage disorders and rare hematology and ophthalmology disorders.
  • Following the launch of our new rare disease business unit, we were honored to meet with many members of the lysosomal storage disease community at the recent WORLDSymposium meeting in Orlando, said Giacomo Chiesi, Head of Chiesi Global Rare Diseases.
  • In 2020, members of the leadership team at Chiesi Global Rare Diseases will meet with leaders from advocacy organizations as well as individual families affected by rare diseases during a global listening tour.
  • Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders.

Chiesi Group Announces Establishment of New Global Rare Diseases Division

Retrieved on: 
Thursday, February 6, 2020
Chiesi Farmaceutici S.p.A., Rare disease

Chiesi Global Rare Diseases unit will harness the full resources of Chiesi Group to support rare disease communities, with initial focus on lysosomal storage disorders, hematology and ophthalmology

Key Points: 
  • Chiesi Global Rare Diseases unit will harness the full resources of Chiesi Group to support rare disease communities, with initial focus on lysosomal storage disorders, hematology and ophthalmology
    BOSTON, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced the formation of Chiesi Global Rare Diseases, a new business unit that will harness the full resources of the Chiesi Group to advance research and new product development for rare and ultra-rare diseases.
  • With the Chiesi Global Rare Diseases unit, we are taking this to an entirely new level rededicating and strengthening our efforts to support individuals and families affected by rare diseases all around the world, said Giacomo Chiesi, Head of Chiesi Global Rare Diseases.
  • Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders.
  • The Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available.

Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium™ 2020

Retrieved on: 
Thursday, January 30, 2020
Protalix BioTherapeutics, Life sciences, Companies, Articles, Taliglucerase alfa, Biotechnology, Chiesi Farmaceutici S.p.A., Biopharmaceutical, Takeda Pharmaceutical Company, Velaglucerase alfa

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx.

Key Points: 
  • Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx.
  • Protalix was the first company to gain U.S.Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system.
  • Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
  • Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)

Retrieved on: 
Monday, January 13, 2020
Chiesi Farmaceutici S.p.A., Pharmaceutical companies, Apotex, Deferiprone

PARMA, Italy, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group) and Apotex, Inc., together with its US subsidiary, ApoPharma USA Inc., an innovative drug company, active in the hematology and neurodegeneration therapeutic areas, today announced that Chiesi Group has finalized an agreement for the acquisition of the worldwide rights to Ferriprox (deferiprone).

Key Points: 
  • PARMA, Italy, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group) and Apotex, Inc., together with its US subsidiary, ApoPharma USA Inc., an innovative drug company, active in the hematology and neurodegeneration therapeutic areas, today announced that Chiesi Group has finalized an agreement for the acquisition of the worldwide rights to Ferriprox (deferiprone).
  • Chiesi Group previously served as a distributor of Ferriprox in Italy, Brazil, Turkey and certain other countries.
  • The team of approximately 50 ApoPharma employees will transition to Chiesi Group, providing a foundation for Chiesi to establish offices in Toronto, Canada.
  • We very much look forward to integrating the ApoPharma team into our organization, said Giacomo Chiesi, Head of Chiesi Global Rare Diseases.